PembrolizumabMyocarditis with myositis/myasthenia gravis overlap syndrome

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2006卷 / 1期

关键词：

D O I：

10.1007/s40278-024-58465-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：570 / 570

相关论文

共 50 条

[21] Gemcitabine/paclitaxel/serplulimabLack of efficacy and myocarditis-myositis-myasthenia gravis overlap syndrome: case report
Reactions Weekly, 2025, 2053 (1) : 167 - 167
[22] PembrolizumabOverlap syndrome of myasthenia gravis and myositis: case report
Reactions Weekly, 2021, 1844 (1) : 368 - 368
[23] Methylprednisolone/nivolumabLack of efficacy and overlap of myocarditis, myositis and myasthenia gravis : case report
Reactions Weekly, 2023, 1963 (1) : 334 - 334
[24] MYASTHENIA GRAVIS AND LAMBERT EATON MYASTHENIC OVERLAP SYNDROME
Tsao, B. E.
Escutin, R. O.
Peterson, G. W.
MUSCLE & NERVE, 2012, 46 (04) : 647 - 648
[25] MYASTHENIA GRAVIS LAMBERT-EATON OVERLAP SYNDROME
Oh, Shin J.
MUSCLE & NERVE, 2016, 53 (01) : 20 - 26
[26] Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases
Pathak, Ranjan
Katel, Anjan
Massarelli, Erminia
Villaflor, Victoria M.
Sun, Virginia
Salgia, Ravi
ONCOLOGIST, 2021, 26 (12): : 1052 - 1061
[27] Pembrolizumab/rituximabMyocarditis, myositis-myasthenia gravis overlap syndrome and B-cell depletion: case report
Reactions Weekly, 2019, 1761 (1) : 301 - 301
[28] Durvalumab/rituximabMyocarditis-myositis-myasthenia gravis (Triple-M) overlap syndrome and lack of efficacy: case report
Reactions Weekly, 2025, 2052 (1) : 164 - 164
[29] A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma
Newman, Matthew T.
Bikhchandani, Mihir
CANCER REPORTS, 2024, 7 (07)
[30] Immune globulin/pembrolizumabNeuromuscular overlap syndrome with coexisting clinical features of myasthenia gravis and myositis, and lack of efficacy: case report
Reactions Weekly, 2021, 1865 (1) : 221 - 221

← 1 2 3 4 5 →